Titan Pharmaceuticals (TTNP) Shares Rally on Probuphine Update
Shares of Titan Pharmaceuticals Inc., a biopharmaceutical company engaged in the development of proprietary therapeutics mainly for the treatment of central nervous system disorders, jumped in today’s trading after the company provided an update on its Probuphine™. Titan Pharmaceuticals said that it met with the U.S. FDA for a Pre-New Drug Application (Pre-NDA) meeting relating to Probuphone, which is an innovative subcutaneous implant formulation of buprenorphine. Following the meeting with the FDA, the company believes that its phase III clinical program completed to date is acceptable to the agency to support submission of a NDA through the 505(b)(2) pathway. The…